IVAP Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Inventiva S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.49 |
| 52 Week High | €5.12 |
| 52 Week Low | €2.49 |
| Beta | 1.03 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -79.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| IVAP | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -3.6% | -0.6% |
| 1Y | n/a | -27.0% | 5.4% |
Return vs Industry: Insufficient data to determine how IVAP performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how IVAP performed against the UK Market.
Price Volatility
| IVAP volatility | |
|---|---|
| IVAP Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.2% |
| 10% least volatile stocks in GB Market | 2.8% |
Stable Share Price: IVAP has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IVAP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 111 | Frederic Cren | www.inventivapharma.com |
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease.
Inventiva S.A. Fundamentals Summary
| IVAP fundamental statistics | |
|---|---|
| Market cap | €157.63m |
| Earnings (TTM) | -€54.27m |
| Revenue (TTM) | €18.81m |
8.4x
P/S Ratio-2.9x
P/E RatioIs IVAP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IVAP income statement (TTM) | |
|---|---|
| Revenue | €18.81m |
| Cost of Revenue | €995.00k |
| Gross Profit | €17.82m |
| Other Expenses | €72.09m |
| Earnings | -€54.27m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
Sep 28, 2023
| Earnings per share (EPS) | -1.29 |
| Gross Margin | 94.71% |
| Net Profit Margin | -288.48% |
| Debt/Equity Ratio | 87.7% |
How did IVAP perform over the long term?
See historical performance and comparison